242 related articles for article (PubMed ID: 18476293)
1. Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
; Lundgren JD; Babiker A; El-Sadr W; Emery S; Grund B; Neaton JD; Neuhaus J; Phillips AN
J Infect Dis; 2008 Apr; 197(8):1145-55. PubMed ID: 18476293
[TBL] [Abstract][Full Text] [Related]
2. CD4+ count-guided interruption of antiretroviral treatment.
; El-Sadr WM; Lundgren J; Neaton JD; Gordin F; Abrams D; Arduino RC; Babiker A; Burman W; Clumeck N; Cohen CJ; Cohn D; Cooper D; Darbyshire J; Emery S; Fätkenheuer G; Gazzard B; Grund B; Hoy J; Klingman K; Losso M; Markowitz N; Neuhaus J; Phillips A; Rappoport C
N Engl J Med; 2006 Nov; 355(22):2283-96. PubMed ID: 17135583
[TBL] [Abstract][Full Text] [Related]
3. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study.
; Emery S; Neuhaus JA; Phillips AN; Babiker A; Cohen CJ; Gatell JM; Girard PM; Grund B; Law M; Losso MH; Palfreeman A; Wood R
J Infect Dis; 2008 Apr; 197(8):1133-44. PubMed ID: 18476292
[TBL] [Abstract][Full Text] [Related]
4. Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
; El-Sadr WM; Grund B; Neuhaus J; Babiker A; Cohen CJ; Darbyshire J; Emery S; Lundgren JD; Phillips A; Neaton JD
Ann Intern Med; 2008 Sep; 149(5):289-99. PubMed ID: 18765698
[TBL] [Abstract][Full Text] [Related]
5. Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.
Hogg RS; Yip B; Chan KJ; Wood E; Craib KJ; O'Shaughnessy MV; Montaner JS
JAMA; 2001 Nov; 286(20):2568-77. PubMed ID: 11722271
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
Ruiz L; Paredes R; Gómez G; Romeu J; Domingo P; Pérez-Alvarez N; Tambussi G; Llibre JM; Martínez-Picado J; Vidal F; Fumaz CR; Clotet B;
AIDS; 2007 Jan; 21(2):169-78. PubMed ID: 17197807
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of changes in CD4 count and HIV RNA during the first six months on highly active antiretroviral therapy in chronic human immunodeficiency virus infection.
Ormaasen V; Bruun JN; Sandvik L; Holberg-Petersen M; Gaarder PI
Scand J Infect Dis; 2003; 35(6-7):383-8. PubMed ID: 12953949
[TBL] [Abstract][Full Text] [Related]
8. Comparison of prognostic importance of latest CD4+ cell count and HIV RNA levels in patients with advanced HIV infection on highly active antiretroviral therapy.
MacArthur RD; Perez G; Walmsley S; Baxter JD; Mullin CM; Neaton JD; ;
HIV Clin Trials; 2005; 6(3):127-35. PubMed ID: 16192247
[TBL] [Abstract][Full Text] [Related]
9. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus.
Lawrence J; Mayers DL; Hullsiek KH; Collins G; Abrams DI; Reisler RB; Crane LR; Schmetter BS; Dionne TJ; Saldanha JM; Jones MC; Baxter JD;
N Engl J Med; 2003 Aug; 349(9):837-46. PubMed ID: 12944569
[TBL] [Abstract][Full Text] [Related]
10. Highly active antiretroviral therapy (HAART) retreatment in patients on CD4-guided therapy achieved similar virologic suppression compared with patients on continuous HAART: the HIV Netherlands Australia Thailand Research Collaboration 001.4 study.
Ananworanich J; Siangphoe U; Hill A; Cardiello P; Apateerapong W; Hirschel B; Mahanontharit A; Ubolyam S; Cooper D; Phanuphak P; Ruxrungtham K
J Acquir Immune Defic Syndr; 2005 Aug; 39(5):523-9. PubMed ID: 16044002
[TBL] [Abstract][Full Text] [Related]
11. Extended antiretroviral treatment interruption in HIV-infected patients with long-term suppression of plasma HIV RNA.
Achenbach CJ; Till M; Palella FJ; Knoll MD; Terp SM; Kalnins AU; Murphy RL
HIV Med; 2005 Jan; 6(1):7-12. PubMed ID: 15670246
[TBL] [Abstract][Full Text] [Related]
12. Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.
Imaz A; Olmo M; Peñaranda M; Gutiérrez F; Romeu J; Larrousse M; Domingo P; Oteo JA; Curto J; Vilallonga C; Masiá M; López-Aldeguer J; Iribarren JA; Podzamczer D;
Antivir Ther; 2013; 18(1):125-30. PubMed ID: 22805174
[TBL] [Abstract][Full Text] [Related]
13. Impact of baseline viral load and adherence on survival of HIV-infected adults with baseline CD4 cell counts > or = 200 cells/microl.
Wood E; Hogg RS; Yip B; Moore D; Harrigan PR; Montaner JS
AIDS; 2006 May; 20(8):1117-23. PubMed ID: 16691062
[TBL] [Abstract][Full Text] [Related]
14. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N; Uthman OA; Rutherford GW
Cochrane Database Syst Rev; 2010 Mar; 2010(3):CD008272. PubMed ID: 20238364
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness implications of the timing of antiretroviral therapy in HIV-infected adults.
Schackman BR; Freedberg KA; Weinstein MC; Sax PE; Losina E; Zhang H; Goldie SJ
Arch Intern Med; 2002 Nov; 162(21):2478-86. PubMed ID: 12437408
[TBL] [Abstract][Full Text] [Related]
16. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection.
Hecht FM; Wang L; Collier A; Little S; Markowitz M; Margolick J; Kilby JM; Daar E; Conway B; Holte S;
J Infect Dis; 2006 Sep; 194(6):725-33. PubMed ID: 16941337
[TBL] [Abstract][Full Text] [Related]
17. Declining prevalence of opportunistic gastrointestinal disease in the era of combination antiretroviral therapy.
Mönkemüller KE; Call SA; Lazenby AJ; Wilcox CM
Am J Gastroenterol; 2000 Feb; 95(2):457-62. PubMed ID: 10685750
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 therapy in patients with HIV infection.
; ; Abrams D; Lévy Y; Losso MH; Babiker A; Collins G; Cooper DA; Darbyshire J; Emery S; Fox L; Gordin F; Lane HC; Lundgren JD; Mitsuyasu R; Neaton JD; Phillips A; Routy JP; Tambussi G; Wentworth D
N Engl J Med; 2009 Oct; 361(16):1548-59. PubMed ID: 19828532
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team.
Currier JS; Williams PL; Koletar SL; Cohn SE; Murphy RL; Heald AE; Hafner R; Bassily EL; Lederman HM; Knirsch C; Benson CA; Valdez H; Aberg JA; McCutchan JA
Ann Intern Med; 2000 Oct; 133(7):493-503. PubMed ID: 11015162
[TBL] [Abstract][Full Text] [Related]
20. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.
Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A
JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
